prothymosin alpha raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-05 and is reviewed periodically as new material appears.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Assessed by visual inspection at release |
| Solubility class | Freely soluble in water | Aqueous buffers near neutral pH |
| Typical storage temperature | Minus 20 degrees Celsius | Lyophilized, desiccated, protected from light |
| Typical analytical method | Reverse-phase HPLC with mass spectrometry | Used together for purity and identity |
| Common synonyms | T-alpha-1; thymalfasin | Older reports use several designations |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
March 12: Law expanding the civil capacity of professional unions; married women may join and participate (including in administration and leadership) without their husband's permission. July 31: Law criminalizing incitement to abortion and anti-contraceptive propaganda. August 12: Decree enacting the Peace Treaty of November 27, 1919, which created the League of Nations (SDN) and established principles such as the prohibition of child labor, restrictions on youth labor for both sexes, and "equal pay for equal work"; women may be technical advisors within the SDN on certain topics. 1921
STRIDE: A Microsoft model that identifies threats across six categories: spoofing, tampering, repudiation, information disclosure, denial of service, and elevation of privilege. MITRE ATLAS: A knowledge base of adversary tactics and techniques for AI systems. OWASP GenAI Security Project: Provides guidance on vulnerabilities associated with generative AI and large language model integration, including guidelines specifically for agentic applications. MAESTRO: A framework from the Cloud Security Alliance for assessing risks in AI systems throughout their lifecycle.
Til the Casket Drops (2009) was the final Clipse album before the duo split to make solo material. The breakup was initiated by Malice, who had multiple conversations with Pusha T about quitting the duo; the first time was after a studio session with Rick Rubin. Toward the end of the duo's partnership, their then-manager and various people in their personal lives were arrested on drug charges. One day, when both brothers were to board a plane, Pusha T was unusually late, and Malice worried that he had been arrested; although Pusha T eventually boarded, it was the final straw for Malice, who angrily declared to his brother in front of the other passengers that he was done with the duo. Although the breakup wasn't made public at the time, rumors that the duo was over began when Malice (then named Malicious) changed his stage name to No Malice, converted to Christianity, and started making Christian rap, as opposed to the "coke rap" of Clipse. In 2014, he firmly denied the possibility of a reunion. His attitude had softened by 2016: "I'ma tell you that I learned to never say never, and I don't shut the door on anything. I really don't. In fact, I would like to see Clipse do it. But I just do things differently." The duo appeared together (credited as Clipse) on "Use This Gospel" by Kanye West, from his Christian hip-hop and gospel album Jesus Is King (2019), having also worked on a demo version of "Follow God". Speaking on the reunion, Pusha T said: "I'm the younger brother, man.
Sources: en.wikipedia.org
One of the best-known examples of convergent evolution is the camera eye of cephalopods (such as squid and octopus), vertebrates (including mammals) and cnidarians (such as jellyfish). Their last common ancestor had at most a simple photoreceptive spot, but a range of processes led to the progressive refinement of camera eyes—with one sharp difference: the cephalopod eye is "wired" in the opposite direction, with blood and nerve vessels entering from the back of the retina, rather than the front as in vertebrates. As a result, vertebrates have a blind spot.
=== Multiple equilibria === Two or more equilibria can exist at the same time. When this is so, equilibrium constants can be ascribed to individual equilibria, but they are not always unique. For example, three equilibrium constants can be defined for a dibasic acid, H2A.
Andean textiles Chakitaqlla Chinchaypujio District Chuspas Indigenous peoples in Argentina Indigenous peoples in Bolivia Indigenous peoples in Ecuador Indigenous peoples of Peru Inkarrí Kichwa Quechuan languages Secret of the Incas, movie with conversation and singing in Quechua Sumak kawsay Yanantin
Alfred Russel Wallace's 1879 book Australasia, Ian Todd's 1974 book Island Realm: A Pacific Panorama and Dean Kohlhoff's 2002 book Amchitka and the Bomb: Nuclear Testing in Alaska all associate the Aleutian Islands with the Oceania region due to their status as remote islands in the Pacific. The islands, having biogeographical and ethnocultural affinities to North America, are not ordinarily considered a part of the region.
Sources: en.wikipedia.org
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.
It establishes that the measured mass matches the expected value for the intact molecule. It also helps detect modifications such as oxidation or truncation that shift the mass by a known amount.
Cycling between frozen and liquid states can promote aggregation and adsorption to container walls. Dividing a stock into single-use aliquots limits the number of cycles a given vial undergoes.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.